CHICAGO (AP) - Abbott Laboratories halted a trial of a key drug after it failed to slow the progression of prostate cancer, the company said Monday.
The drug Atrasentan was in a study for the treatment of end-stage prostate cancer patients, and did show some positive effects, Abbott said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!